{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'In addition, subgroup analyses may be conducted for selected endpoints to determine whether', 'the treatment effect is consistent. Subgroups may include but are not limited to the following:', 'Age category years; < 75 VS > 75 years)', 'Sex (female VS male)', 'Prior platinum (cisplatin VS carboplatin VS both)', 'Prior lines of systemic therapy in locally advanced or metastatic setting (1 to 2 VS > 3)', 'Best response to most recent CPI (responder VS non-responder) CPI most recent', 'treatment (yes VS no)', 'Baseline hemoglobin (> 10 VS < 10 g/dL)', 'Histology (Urothelial Carcinoma/transitiona cell VS Urothelial Carcinoma mixed VS', 'other)', 'Primary site of tumor (upper tract VS bladder/other)', 'Smoking status (never VS former VS current)', 'Brain metastasis status (prior brain metastasis vs no prior brain metastasis)', \"Investigators' choice of paclitaxel/docetaxe or vinflunine\", 'Baseline Nectin-4 IHC score (<150 VS 150 - 225 VS >225)', 'Prior taxane (yes VS no)', 'PD-L1 CPS', '7.4.4', 'Analysis of Exploratory Enppoints', 'Exploratory analysis for efficacy endpoints will be discussed in the statistical analysis plan.', 'Serum or plasma TAb, ADC and MMAE concentrations will be summarized with descriptive', 'statistics at each PK sampling time point using the PK analysis set. These data may be', 'combined with data from previous studies for population PK and PK/PD analyses. The', 'relationship between TAb, ADC, MMAE and PD endpoints, safety, or efficacy may be', 'explored.', 'The incidence of ATA will be summarized by visit and overall using the safety analyses set.', '7.5', 'Analysis of Safety', 'SAF will be used to perform all safety analysis. All treated subjects will be analyzed', 'according to the treatment they received.', '7.5.1', 'Adverse Events', 'AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).', 'A TEAE is defined as an AE observed or worsened after starting administration of the study', 'drug.', 'The number and percentage of subjects with treatment-emergent AEs, SAEs, AEs leading to', 'withdrawal of treatment, and AEs related to study drug will be summarized by system organ', 'class, preferred term and treatment group. The number and percentage of AEs by severity', 'will also be summarized. All AEs will be listed.', '14 Sep 2020', 'Astellas', 'Page 89 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'A study drug-related TEAE is defined as any TEAE with a causal relationship of YES by the', 'investigator. AEs of interest as classified by customized MedDRA queries and/or standard', 'MedDRA queries will also be summarized.', '7.5.2', 'Laboratory Assessments', 'For quantitative laboratory measurements descriptive statistics will be used to summarize', 'results and change from baseline for subjects in the SAF by treatment group and time point.', 'Shifts relative to normal ranges from baseline to each time point during treatment period in', 'lab tests will also be tabulated. Laboratory data will be displayed in listings.', '7.5.3', 'Vital Signs', 'Vital sign results and changes from baseline at scheduled visits will be summarized with', 'descriptive statistics for subjects in the SAF by treatment group. Vital signs data will be', 'displayed in listings.', '7.5.4', 'Routine 12-lead Electrocardiograms', 'The 12-lead ECG results will be summarized by treatment group and time point.', '7.5.5', 'ECOG Performance Status', 'Summary statistics (number and percent of subjects) for each category of the ECOG PS at', 'each assessment will be provided. The change from baseline to final visit or early termination', 'will also be summarized. Negative change scores indicate an improvement. Positive scores', 'indicate a decline in performance.', '7.5.6', 'Exposure-Response Relationship Analysis', 'Relationships between TAb, ADC and MMAE concentrations and certain efficacy or safety', 'endpoints may be analyzed in an exploratory manner. Further details of these analyses will be', 'described in an exposure-response analysis plan.', '7.6', 'Analysis of Pharmacokinetics', 'Individual and summary tables of serum TAb and ADC and plasma MMAE concentrations', 'and a listing of blood collection times and concentrations will be provided.', 'Summary statistics will be provided including n, mean, SD, geometric mean, minimum,', 'median, maximum, and %CV. Values below the lower limit of quantification (BLOQ) will be', 'set to not be calculated if all values are BLOQ. In cases where more than half of the', 'individual data in a group are BLOQ, the geometric mean will not be calculated. Additional', 'model-based analyses may be performed and will be described in a separate population PK', 'analysis plan.', '7.7', 'Major Protocol Deviations and Other Analyses', 'Major protocol deviations as defined in [Section 8.1.6 Major Protocol Deviations) will be', 'summarized for all randomized subjects by treatment group and total as well as by site. A', 'data listing will be provided by site and subject.', '14 Sep 2020', 'Astellas', 'Page 90 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}